Celcuity posts better-than-expected Q4 adjusted net loss

Reuters03-26 04:16

Celcuity posts better-than-expected Q4 adjusted net loss

Overview

U.S. biotech firm's Q4 adjusted EPS comes in better than expectations
Adjusted net loss for Q4 also comes in better than analyst expectations

Outlook

Celcuity expects topline results from PIK3CA mutant cohort in Q2 2026
Company preparing for potential commercial launch of gedatolisib in Q3 2026

Result Drivers

R&D AND LAUNCH COSTS - Higher Q4 operating expenses driven by increased R&D and commercial launch-related activities
HIGHER G&A EXPENSES - Increase in G&A expenses mainly due to higher employee-related and consulting costs, including non-cash stock-based compensation

Company press release: ID:nGNX65pryF

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Adjusted EPS	Beat	-$0.73	-$1.04 (10 Analysts)
Q4 EPS		-$0.97
Q4 Adjusted Net Income	Beat	-$38.4 mln	-$47.76 mln (9 Analysts)
Q4 Net Income		-$51 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Celcuity Inc is $120.00, about 17.6% above its March 24 closing price of $102.01

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622004204?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 04:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622004204","market":"fut","top_or_hot":-1,"title":"Celcuity posts better-than-expected Q4 adjusted net loss","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Celcuity posts better-than-expected Q4 adjusted net loss</title></head><body><p><span>Overview</span></p><ul><li><p>U.S. biotech firm's Q4 adjusted EPS comes in better than expectations</p></li><li><p>Adjusted net loss for Q4 also comes in better than analyst expectations</p></li></ul><p><span>Outlook</span></p><ul><li><p>Celcuity expects topline results from PIK3CA mutant cohort in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026</p></li><li><p>Company preparing for potential commercial launch of gedatolisib in Q3 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D AND LAUNCH COSTS - Higher Q4 operating expenses driven by increased R&amp;D and commercial launch-related activities</p></li><li><p>HIGHER G&amp;A EXPENSES - Increase in G&amp;A expenses mainly due to higher employee-related and consulting costs, including non-cash stock-based compensation</p></li></ul><p>Company press release: <span>ID:nGNX65pryF</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Adjusted EPS</p></td><td><p>Beat</p></td><td><p>-$0.73</p></td><td><p>-$1.04 (10 Analysts)</p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>-$0.97</p></td><td></td></tr><tr><td><p>Q4 Adjusted Net Income</p></td><td><p>Beat</p></td><td><p>-$38.4 mln</p></td><td><p>-$47.76 mln (9 Analysts)</p></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$51 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 10 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/CELC\">Celcuity Inc</a> is $120.00, about 17.6% above its March 24 closing price of $102.01</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Celcuity posts better-than-expected Q4 adjusted net loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCelcuity posts better-than-expected Q4 adjusted net loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-26 04:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Celcuity posts better-than-expected Q4 adjusted net loss</title></head><body><p><span>Overview</span></p><ul><li><p>U.S. biotech firm's Q4 adjusted EPS comes in better than expectations</p></li><li><p>Adjusted net loss for Q4 also comes in better than analyst expectations</p></li></ul><p><span>Outlook</span></p><ul><li><p>Celcuity expects topline results from PIK3CA mutant cohort in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026</p></li><li><p>Company preparing for potential commercial launch of gedatolisib in Q3 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D AND LAUNCH COSTS - Higher Q4 operating expenses driven by increased R&amp;D and commercial launch-related activities</p></li><li><p>HIGHER G&amp;A EXPENSES - Increase in G&amp;A expenses mainly due to higher employee-related and consulting costs, including non-cash stock-based compensation</p></li></ul><p>Company press release: <span>ID:nGNX65pryF</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Adjusted EPS</p></td><td><p>Beat</p></td><td><p>-$0.73</p></td><td><p>-$1.04 (10 Analysts)</p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>-$0.97</p></td><td></td></tr><tr><td><p>Q4 Adjusted Net Income</p></td><td><p>Beat</p></td><td><p>-$38.4 mln</p></td><td><p>-$47.76 mln (9 Analysts)</p></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$51 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 10 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/CELC\">Celcuity Inc</a> is $120.00, about 17.6% above its March 24 closing price of $102.01</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL1N40D13C:1","article_id":"2622004204","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622004204","pubTimestamp":1774469771,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Celcuity posts better-than-expected Q4 adjusted net lossOverviewU.S. biotech firm's Q4 adjusted EPS comes in better than expectationsAdjusted net loss for Q4 also comes in better than analyst expectat","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CELC":"Celcuity Inc"},"translate_title":"Celcuity公布第四季度调整后净亏损好于预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CELC":0.9},"content_text":"Celcuity posts better-than-expected Q4 adjusted net lossOverviewU.S. biotech firm's Q4 adjusted EPS comes in better than expectationsAdjusted net loss for Q4 also comes in better than analyst expectationsOutlookCelcuity expects topline results from PIK3CA mutant cohort in Q2 2026Company preparing for potential commercial launch of gedatolisib in Q3 2026Result DriversR&D AND LAUNCH COSTS - Higher Q4 operating expenses driven by increased R&D and commercial launch-related activitiesHIGHER G&A EXPENSES - Increase in G&A expenses mainly due to higher employee-related and consulting costs, including non-cash stock-based compensationCompany press release: ID:nGNX65pryFKey DetailsMetricBeat/MissActualConsensus EstimateQ4 Adjusted EPSBeat-$0.73-$1.04 (10 Analysts)Q4 EPS-$0.97Q4 Adjusted Net IncomeBeat-$38.4 mln-$47.76 mln (9 Analysts)Q4 Net Income-$51 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 10 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Celcuity Inc is $120.00, about 17.6% above its March 24 closing price of $102.01For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622004204","isCrawlerRequest":true}